Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

@inproceedings{Wilding2018ChangesIH,
  title={Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink},
  author={John Wilding and Thomas R. Godec and Kamlesh Khunti and Stuart J. Pocock and Kenneth R Fox and Liam Smeeth and Per Clauson and Peter Fenici and Niklas Hammar and Jes{\'u}s Manuel Pollo Medina},
  booktitle={BMC medicine},
  year={2018}
}
BACKGROUND Intensification of metformin monotherapy with additional glucose-lowering drugs is often required in patients with type 2 diabetes (T2D). This study evaluated changes in HbA1c and weight, as well as treatment persistence, associated with different second-line therapies used in UK clinical practice. METHODS The UK Clinical Practice Research Datalink was used to identify patients with T2D who initiated second-line therapy after metformin monotherapy between 1 August 2013 and 14 June… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

Wiviott SD DECLARE-TIMI 58: design and baseline characteristics

  • I Raz, MP Bonaca, +11 authors MS Sabatine
  • Diabetes Obes Metab
  • 2018
1 Excerpt

Similar Papers

Loading similar papers…